TP53 and major depressive disorder: Among the 12 shared targets, TP53, JUN, CASP3, PTGS2 showed no significant expression changes (p > 0.05), whereas SIRT3 exhibited marked dysregulation (p < 0.01) and PTK2 demonstrated no significant difference (p > 0.05) in MDD cohorts (Figure 6).